An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer

Introduction: Multikinase inhibitors have clinical activity in radioactive iodine refractory (RAIR) differentiated thyroid cancers (DTCs) but are not curative; optimal management and salvage therapies remain unclear. This study assessed clinical effects of pazopanib therapy in RAIR-DTC patients with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thyroid
Autors principals: Bible, Keith C., Menefee, Michael E., Lin, Chia-Chi (Josh), Millward, Michael J., Maples, William J., Goh, Boon Cher, Karlin, Nina J., Kane, Madeleine A., Adkins, Douglas R., Molina, Julian R., Donehower, Ross C., Lim, Wan-Teck, Flynn, Patrick J., Richardson, Ronald L., Traynor, Anne M., Rubin, Joseph, LoRusso, Patricia M., Smallridge, Robert C., Burton, Jill K., Suman, Vera J., Kumar, Aditi, Voss, Jessie S., Rumilla, Kandalaria M., Kipp, Benjamin R., Chintakuntlawar, Ashish V., Harris, Pamela, Erlichman, Charles
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc., publishers 2020
Matèries:
Thyroid Cancer and Nodules
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7482116/
https://ncbi.nlm.nih.gov/pubmed/32538690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2019.0269
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars